Compare Adaptive Biotechnologies Corp (ADPT) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Phillips 66 — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Phillips 66 trades at $225.5 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 22.2× Adaptive Biotechnologies Corp's market cap, and Phillips 66 pays a 2.26% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PSX | |
|---|---|---|
Market Cap | $4.04B | $89.52B |
Sector | Health | Energy |
52-Week High | $25.45 | $224.36 |
52-Week Low | $12.30 | $120.04 |
Enterprise Value | $4.10B | $105.99B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Phillips 66 (PSX) trades at $225.48, up 4.62% today, with a bullish technical signal supported by moving averages and strong earnings beats. Recent Q2 2026 EPS of $9.41 exceeded expectations, driven by robust refining margins. The company announced a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream operations. Valuation metrics appear attractive with a P/E of 12.81 and P/S of 0.6, while profitability remains solid with a 24.02% ROE.
Outlook is positive due to sustained refining tightness and debt reduction, but risks include volatile crude prices and regulatory pressures. Analysts are bullish with a $221.92 consensus target, though the stock faces near-term resistance at $227. Revenue is projected to rebound to $152.2B in 2026, supporting a hold or buy stance for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
